Nanobiotix ( (NBTX) ) has shared an announcement.
On February 12, 2025, Nanobiotix announced its voting rights and shares capital data, reflecting 47,426,851 outstanding shares with 49,208,659 theoretical voting rights and 49,186,541 exercisable voting rights as of January 31, 2025. This disclosure is in line with regulatory requirements, ensuring transparency regarding the distribution and exercise of voting rights, which is crucial for stakeholders’ informed decision-making.
More about Nanobiotix
Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris, France, specializing in innovative, physics-based therapeutic approaches. Founded in 2003, the company focuses on oncology, bioavailability, biodistribution, and central nervous system disorders, holding over 25 patent families across three nanotechnology platforms. It is listed on Euronext Paris and the Nasdaq Global Select Market.
YTD Price Performance: 42.07%
Average Trading Volume: 33,459
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $187.9M
See more insights into NBTX stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com